Filtered By:
Cancer: Prostate Cancer
This page shows you your search results in order of date. This is page number 14.
Order by Relevance | Date
Total 25749 results found since Jan 2013.
Sustainable Nanoparticles from Stephania glabra and Analysis of Their Anticancer Potential on 2D and 3D Models of Prostate Cancer
Appl Biochem Biotechnol. 2023 Sep 8. doi: 10.1007/s12010-023-04700-w. Online ahead of print.ABSTRACTIn pursuit of a novel effective treatment for prostate cancer, methanolic extract of Stephania glabra tubers (Sg-ME) was utilized to fabricate silver (Sg-AgNP), copper oxide (Sg-CuONP), and silver-copper bimetallic nanoparticles (Sg-BNP). The characterization of the nanoparticles confirmed spherical shape with average diameters of 30.72, 32.19, and 25.59 nm of Sg-AgNP, Sg-CuONP, and Sg-BNP, respectively. Interestingly, these nanoparticles exhibited significant cytotoxicity toward the prostate cancer (PC3) cell line while bei...
Source: Applied Biochemistry and Biotechnology - September 8, 2023 Category: Biochemistry Authors: Prachi Vaid Adesh K Saini Raju Kumar Gupta Eshu Singhal Sinha Deepak Sharma Walaa F Alsanie Vijay Kumar Thakur Reena V Saini Source Type: research
Reduction of PTV margins for elective pelvic lymph nodes in online adaptive radiotherapy of prostate cancer patients
CONCLUSION: It is safe to reduce the PTV margin from 5 to 4 mm for the elective pelvic lymph nodes for prostate patients treated with oART. Further margin reductions can be motivated for patients presenting little intrafraction motion.PMID:37682727 | DOI:10.1080/0284186X.2023.2252584
Source: Acta Oncologica - September 8, 2023 Category: Cancer & Oncology Authors: John Alfred Brenns æter Tordis Johnsen Dahle Jannicke N økling Moi Ingvild F ørsvoll Svanberg Gry Sandvik Haaland Sara Pilskog Source Type: research
Impact of 18F-DCFPyL PET/MRI in Selecting Men With Low-/Intermediate-Risk Prostate Cancer for Focal Ablative Therapies
CONCLUSIONS: 18F-DCFPyL PET/MRI excluded nearly 30% of patients with low-/intermediate-risk PCa from FT, with a potential role in decreasing selection failure. Compared with mpMRI, PET/MRI had a higher sensitivity for detecting csPCa in men who were candidates for FT.ClinicalTrials.gov identifier NCT03149861.PMID:37682613 | DOI:10.1097/RLU.0000000000004819
Source: Clinical Prostate Cancer - September 8, 2023 Category: Cancer & Oncology Authors: Adriano Basso Dias Sangeet Ghai Claudia Ortega Seyed Ali Mirshahvalad Nathan Perlis Alejandro Berlin Lisa Avery Patrick Veit-Haibach Theodorus van der Kwast Ur Metser Source Type: research
Noninvasive Verification of a Very Small Intraocular Prostate Carcinoma Metastasis by 68Ga-PSMA-11 PET/CT
Clin Nucl Med. 2023 Oct 1;48(10):915-916. doi: 10.1097/RLU.0000000000004790. Epub 2023 Aug 30.ABSTRACTA male patient underwent 68Ga-PSMA-11 PET/CT for the evaluation of a suspected intraocular metastasis in the right eye. Although the choroidal thickening was very small (4 × 2 mm), and ophthalmoscopy as well as MRI were inconclusive, PET/CT imaging showed distinct PSMA expression in the suspected lesion, confirming prostate cancer metastasis. The ability of dedicated PSMA ligand PET/CT imaging to detect small metastases, even with 68Ga-labeled ligands, has been demonstrated. Therefore, the use of further invasive diagnost...
Source: Clinical Prostate Cancer - September 8, 2023 Category: Cancer & Oncology Authors: Ferdinand Ndum Philipp Seifert Martin Freesmeyer Falk G ühne Source Type: research
68Ga-PSMA-11 PET/CT in a Case of Isolated Parietal Peritoneal Metastasis From Prostate Adenocarcinoma
We present 68Ga-PSMA-11 PET/CT findings in a case of isolated parietal peritoneal metastasis from prostate adenocarcinoma 35 months after radical prostatectomy. The peritoneal metastases showed multifocal intense PSMA uptake, but subtle structural abnormalities on 68Ga-PSMA-11 PET/CT. The patient was subsequently treated with androgen deprivation therapy. The peritoneal metastases progressed 25 months after the initiation of androgen deprivation therapy and were removed surgically. Histologic and immunohistochemical evaluation revealed metastatic prostate adenocarcinoma with treatment-related neuroendocrine differentiation...
Source: Clinical Prostate Cancer - September 8, 2023 Category: Cancer & Oncology Authors: Qian Zhao Aisheng Dong Changjing Zuo Source Type: research
Antitumor activity of alkylphospholipid edelfosine in prostate cancer models and endoplasmic reticulum targeting
Biomed Pharmacother. 2023 Sep 6;167:115436. doi: 10.1016/j.biopha.2023.115436. Online ahead of print.ABSTRACTProstate cancer is the second most frequent cancer and the fifth leading cause of cancer death among men worldwide. While the five-year survival in local and regional prostate cancer is higher than 99%, it falls to about 28% in advanced metastatic prostate cancer. The ether lipid edelfosine is considered the prototype of a family of promising antitumor drugs collectively named as alkylphospholipid analogs. Here, we found that edelfosine was the most potent alkylphospholipid analog in inducing apoptosis in three diff...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - September 8, 2023 Category: Drugs & Pharmacology Authors: El-Habib Dakir Consuelo Gajate Faustino Mollinedo Source Type: research
Sustainable Nanoparticles from Stephania glabra and Analysis of Their Anticancer Potential on 2D and 3D Models of Prostate Cancer
Appl Biochem Biotechnol. 2023 Sep 8. doi: 10.1007/s12010-023-04700-w. Online ahead of print.ABSTRACTIn pursuit of a novel effective treatment for prostate cancer, methanolic extract of Stephania glabra tubers (Sg-ME) was utilized to fabricate silver (Sg-AgNP), copper oxide (Sg-CuONP), and silver-copper bimetallic nanoparticles (Sg-BNP). The characterization of the nanoparticles confirmed spherical shape with average diameters of 30.72, 32.19, and 25.59 nm of Sg-AgNP, Sg-CuONP, and Sg-BNP, respectively. Interestingly, these nanoparticles exhibited significant cytotoxicity toward the prostate cancer (PC3) cell line while bei...
Source: Applied Biochemistry and Biotechnology - September 8, 2023 Category: Biochemistry Authors: Prachi Vaid Adesh K Saini Raju Kumar Gupta Eshu Singhal Sinha Deepak Sharma Walaa F Alsanie Vijay Kumar Thakur Reena V Saini Source Type: research
Relative search popularity of five advanced prostate cancer medications using Google Trends
Prostate Cancer and Prostatic Diseases, Published online: 08 September 2023; doi:10.1038/s41391-023-00716-9Relative search popularity of five advanced prostate cancer medications using Google Trends
Source: Prostate Cancer and Prostatic Diseases - September 8, 2023 Category: Urology & Nephrology Authors: Sanjay Das Nadine A. Friedrich James Daniels G. Cecilia Galvan Jun Gong Edwin Posadas William Aronson Stephen J. Freedland Source Type: research
Impact of Prior Cancer on the Prognosis of Patients with Chondrosarcoma: A Population-Based Study of the SEER Database
CONCLUSION: This study initially discovered that chondrosarcoma patients with past cancer have a bad prognosis. Different types of past cancer have varying effects on survival. We urgently propose that cancer trial exclusion criteria be set specifically by cancer classification, rather than accepting the unchangeable criterion for default.PMID:37678875
Source: Alternative Therapies in Health and Medicine - September 7, 2023 Category: Complementary Medicine Authors: Jun Qian Shijie Dai Haoyu Wang Source Type: research
A meta-analysis of epitopes in prostate-specific antigens identifies opportunities and knowledge gaps
CONCLUSION: CEDAR provides a comprehensive repository of epitopes related to prostate-specific antigens. This inventory of epitope data with its wealth of searchable T cell, B cell and MHC ligand information provides a useful tool for the scientific community. At the same time, we identify significant knowledge gaps that could be addressed by experimental analysis.PMID:37679223 | DOI:10.1016/j.humimm.2023.08.145
Source: Human Immunology - September 7, 2023 Category: Allergy & Immunology Authors: Gabriele Foos Nina Blazeska Morten Nielsen Hannah Carter Zeynep Kosaloglu-Yalcin Bjoern Peters Alessandro Sette Source Type: research
Rising Prostate Cancer Incidence Rates: What Can We Do About It?
Clin J Oncol Nurs. 2023 Mar 16;27(2):109-110. doi: 10.1188/23.CJON.109-110.ABSTRACTThe latest American Cancer Society (ACS, 2023) incidence rates for prostate cancer report an uptick of 3% for the years 2014-2019 after several years of decreased incidence rates; this is the first ACS-reported increase in.PMID:37677839 | DOI:10.1188/23.CJON.109-110
Source: Clinical Prostate Cancer - September 7, 2023 Category: Cancer & Oncology Authors: Ellen Carr Source Type: research
Can contralateral lymph-node metastases be ruled out in prostate cancer patients with only unilaterally positive prostate biopsy?
CONCLUSION: Our study highlights the diagnostic value of bilateral pelvic lymphadenectomy and the need for careful planning in surgery for prostate cancer patients with unilaterally positive prostate biopsy.PMID:37676466 | DOI:10.1007/s10147-023-02407-w
Source: Clinical Prostate Cancer - September 7, 2023 Category: Cancer & Oncology Authors: Bianca Michalik Svenja Engels Leonie Kampmeier Lena Dirks R-Peter Henke Friedhelm Wawroschek Alexander Winter Source Type: research
